Three Motley Fool contributors believe they've identified healthcare stocks in the latter category. Here's why they think Eli ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Mounjaro and Zepbound have seen great success generating huge revenues for Lilly. Lilly has also filed regulatory applications in the United States and EU to seek approval for tirzepatide for ...

Zepbound’s superior efficacy and strategic ... including chronic kidney disease. Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Mounjaro and Zepbound have seen great success generating huge revenues for Lilly. Lilly has also filed regulatory applications in the United States and EU to seek approval for tirzepatide for heart ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in ... to our mission of empowering investor success. We provide a platform for our authors to report ...

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

This analysis is based on information available up to January 17, 2025, and market conditions may have changed since then. Gain an edge in your investment decisions with InvestingPro’s in-depth ...